Skip to main content
. Author manuscript; available in PMC: 2020 Apr 24.
Published in final edited form as: Obstet Gynecol. 2019 Apr;133(4):795–802. doi: 10.1097/AOG.0000000000003171

Table 1.

Estimates of clinical effectiveness by strategy

Observation Niraparib maintenance
Patient cohort PFS (months) Utility* PFS (months) Utility*
All patients 4.22 .83 11.64 .84
Germline BRCA1/2 mutant 5.5 .83 21 .84
Germline BRCA wild type 3.9 .83 9.3 .84
HRD testing, positive 3.8 .83 12.9 .84
HRD testing, negative 3.8 .83 6.9 .84
*

Utility scores adapted from the European Quality of Life scale, 5-Dimensions (EQ-5D-5L) measurements from NOVA trial, Mirza et al. 2016